Specyfika zadań polskiej Policji wobec terroryzmu

This article contains the specificity of the Polish police's work against terrorism, taking into account security, which is the most important human value. It is described basic definitions connected to main topic at the beginning of the article. In addition, there is pre-sented police actions aimed at demonstrating the widely defined fight against terrorism by this armed formation. Article also presented the location of the police in the anti-terrorist system of Poland.Artykuł zawiera specyfikę zadań polskiej Policji wobec terroryzmu, uwzględniając bezpieczeństwo, które jest najważniejszą wartością człowieka. Na artykuł składa się przegląd przedmiotowych definicji oraz prezentacja działań stricte policyjne, mających na celu ukazanie szeroko pojętego zwalczania terroryzmu przez tę uzbrojoną formację. Zaprezentowano również umiejscowienie policji w systemie antyterrorystycznym Polski

Use of single pill combinations in the treatment of arterial hypertension in Poland: The current practice and guidelines, the impact on reimbursement spending and patient co-payment

Background: Clinical guidelines recommend using single pill combinations (SPC) when initiating and intensifying the treatment of arterial hypertension (AH), which is not reflected in the Summaries of Product Characteristics (SMPC) for individual preparations. The drug reimbursement system in Poland (with a few exceptions) does not provide for reimbursement outside the indications specified in the SMPC. Therefore, it excludes the use of SPC under reimbursement. In 2020 the share of SPC in the treatment of AH amounted to 12.8% of unit volume and was lower than the 80% based on the guidelines of the Polish Society of Hypertension. Methods: Using the data from a sample of pharmacies in Poland over the period November–December 2020, the potential was assessed of switching from existing AH therapy with monocomponent drugs containing selected combinations of active ingredients to the equivalent SPC. Results: The potential of switching from AH treatment in the analyzed period using monocomponent drugs with the equivalent SPC amounted to 19% of unit volume (a reduction of 212M units), with the highest switch potential (43.9%) for drugs containing amlodipine. The public payer’s savings would be EUR 12.3 million and patient savings would amount to EUR 5.0 million. Conclusions: Enabling reimbursement of SPC in Poland in line with the clinical guidelines can significantly increase the share of SPC in the treatment of AH, which will result in better health outcomes and a significant reduction in the payer’s drug reimbursement spending and will lower the financial barrier for patients to access this type of treatment